Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
Frequently Asked Questions
What is Market Cap of Endocyte, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Endocyte, Inc. market cap is N/A.
What is the 52-week high for Endocyte, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Endocyte, Inc. 52 week high is N/A as of October 22, 2025.
What is the 52-week low for Endocyte, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Endocyte, Inc. 52 week low is N/A as of October 22, 2025.
What is Endocyte, Inc. stock price today?
Endocyte, Inc. stock price today is $23.99.
What was Endocyte, Inc. stock price yesterday?
Endocyte, Inc. stock price yesterday was $24.00.
What is the PE ratio of Endocyte, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Endocyte, Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of Endocyte, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Endocyte, Inc. P/B ratio is None.
What is Endocyte, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Endocyte, Inc.'s EBITDA is -21.82.
What is the 50-day moving average of Endocyte, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Endocyte, Inc. 50-day moving average is N/A.
